Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ortataxel in recurrent glioblastoma
NCT01989884Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ortataxel in glioblastoma (GBM), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Progression Free Survival at 6 months. Started Nov 2013; status: completed.
02
Drugs
ortataxel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01989884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989884.